Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer ; volume:22 ; number:1 ; day:30 ; month:11 ; year:2020 ; pages:1-13 ; date:12.2020
Breast cancer research ; 22, Heft 1 (30.11.2020), 1-13, 12.2020
- Urheber
-
Zoeller, Jason J.
Vagodny, Aleksandr
Daniels, Veerle W.
Taneja, Krishan
Tan, Benjamin Y.
DeRose, Yoko S.
Fujita, Maihi
Welm, Alana L.
Letai, Anthony
Leverson, Joel D.
Blot, Vincent
Bronson, Roderick T.
Dillon, Deborah A.
Brugge, Joan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-020-01374-8
- URN
-
urn:nbn:de:101:1-2021010907181211006879
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zoeller, Jason J.
- Vagodny, Aleksandr
- Daniels, Veerle W.
- Taneja, Krishan
- Tan, Benjamin Y.
- DeRose, Yoko S.
- Fujita, Maihi
- Welm, Alana L.
- Letai, Anthony
- Leverson, Joel D.
- Blot, Vincent
- Bronson, Roderick T.
- Dillon, Deborah A.
- Brugge, Joan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy
EGFR-TKIs resistance via EGFR-independent signaling pathways
Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy
EGFR-TKIs resistance via EGFR-independent signaling pathways
Synchronous intracellular delivery of EGFR-targeted antibody–drug conjugates by p38-mediated non-canonical endocytosis
Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates
A Podcast Discussion on the Intracranial Efficacy of Antibody–Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
Current state of clinical development of TROP2-directed antibody–drug conjugates for triple-negative breast cancer
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Development and characterization of anti-EGFR protein-drug conjugates for tumor therapy